MACROGENICS INC business relationships

Companies named in MACROGENICS INC’s 10-K filed 2026-03-09, and public companies whose annual reports name MACROGENICS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.1 / 10
AI naming: 100 / 100
Agent readiness: 5 / 100
AI adoption: 0 / 100

Named in MACROGENICS INC’s annual report 6

GILEAD SCIENCES, INC. (GILD)Licensor7.7
“Collaboration and License Agreement by and between the Company and Gilead Sciences, Inc., dated October 14, 2022 (incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K filed by the Company on March 15, 2023)” SEC filing
GILEAD SCIENCES, INC. (GILD)Partner7.7
“The Company is also collaborating with Gilead Sciences, Inc. ( Gilead) on the development of MGD024, a bispecific DART antibody targeting CD123 and CD3 that utilizes its next-generation T-cell engager technology, as well as two additional undisclosed pre-clinical development programs.” SEC filing
INCYTE CORP (INCY)Licensor6.1
“Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $ 150.0 million in 2017.” SEC filing
INCYTE CORP (INCY)Partner6.1
“We are eligible for tiered royalties of 15% to 24% on any global net sales (see Note 10, Royalty Monetization Arrangement, in our consolidated financial statements for further information about ZYNYZ royalties), and we have the option to co-promote retifanlimab with Incyte.” SEC filing
Synaffix B.V.Licensor4.7
“In January 2022, the Company entered into a non-exclusive license agreement with Synaffix B.V., a Lonza company (Synaffix) to develop, manufacture and commercialize up to three antibody-drug conjugate targets using Synaffix's proprietary technology.” SEC filing
TerSera Therapeutics LLCPartner4.7
“The Company's revenue relates to contract development and manufacturing services, agreements with various collaborators, and MARGENZA net product sales (prior to the sale to TerSera Therapeutics LLC (TerSera) in November 2024).” SEC filing

Companies whose annual reports name MACROGENICS INC 2

INCYTE CORP (INCY)names it as licensor6.1
“Retifanlimab licensed from MacroGenics, Inc.” SEC filing
INCYTE CORP (INCY)names it as partner6.1
“We are responsible for the sourcing and manufacturing of ZYNYZ together with our collaborator MacroGenics.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.